MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE
First Claim
Patent Images
1. An oral dosage form comprising memantine or a salt thereof, wherein the dosage form comprises 2.5 to 100 mg of memantine or a salt thereof and provides an in vivo plasma profile comprising:
- a mean Tmax of about 8 or more hours;
a mean Cmax of less than about 100 ng/ml; and
a mean AUC0-∞
of more than about 250 ng h/ml.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer'"'"'s disease or neuropathic pain.
83 Citations
59 Claims
-
1. An oral dosage form comprising memantine or a salt thereof, wherein the dosage form comprises 2.5 to 100 mg of memantine or a salt thereof and provides an in vivo plasma profile comprising:
-
a mean Tmax of about 8 or more hours;
a mean Cmax of less than about 100 ng/ml; and
a mean AUC0-∞
of more than about 250 ng h/ml. - View Dependent Claims (2, 3, 4, 5, 54)
-
-
6. An oral dosage form comprising memantine or a salt thereof, wherein the dosage form comprises 2.5 to 50 mg of memantine or a salt thereof and provides an in vivo plasma profile comprising:
-
a mean Tmax of about 5 or more hours;
a mean Cmax of less than about 50 ng/ml; and
a mean AUC0-∞
of more than about 250 ng h/ml. - View Dependent Claims (7, 8, 55)
-
- 9. An oral dosage form comprising 2.5 to 100 mg memantine or a salt thereof wherein the dosage form has a dissolution rate of the active ingredient of about 70% to about 80% within about 4 hours to about 24 hours and a Cmax of less than about 100 ng/ml, wherein the dosage form provides a reduced incidence of adverse events.
-
10. An oral dosage form comprising a plurality of beads, wherein each bead comprises:
-
a core having a diameter from about 1 μ
m to about 1000 μ
m and an active ingredient comprising memantine or a salt thereof in the range of about 15 to about 350 mg/g of the dosage form,wherein the oral dosage form has a dissolution rate of the active ingredient of more than about 80% within about the first 60 minutes following entry of the dosage form into a use environment. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 57)
-
-
33. An oral dosage form comprising a plurality of beads, each bead comprising
a core having a diameter from about 1 μ - m to about 1000 μ
m;
an active ingredient comprising memantine or a salt thereof in the range of about 15 to about 350 mg/g of the dosage form; and
a release modifying polymer layer, wherein the oral dosage form has a dissolution rate of the active ingredient of about 70% to about 80% within about 4 hours to about 24 hours; and
wherein the Cmax is less than about 100 ng/ml. - View Dependent Claims (34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 58)
- m to about 1000 μ
-
51. A composite dosage form comprising an immediate release component and a modified release component,
wherein the immediate release component comprises a first plurality of beads, each bead comprising a first active ingredient comprising memantine or a salt thereof in the range of about 15 to about 350 mg/g of the dosage form, wherein about 80% of the first active ingredient dissolves within about the first 60 minutes following entry of the dosage form into a use environment; - and
wherein the modified release component comprises a second plurality of beads, each bead comprising a second active ingredient comprising memantine or a salt thereof in the range of about 15 to about 350 mg/g of the dosage form, wherein about 70% to about 80% of the second active ingredient dissolves within about 4 hours to about 24 hours following entry of the dosage form into the use environment. - View Dependent Claims (52, 53, 59)
- and
Specification